NCT02107365 - Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

April 30, 2015

Conditions

Hepatitis C Virus Genotype 4 Infection

Interventions

DRUG

Asunaprevir

Asunaprevir 100 mg, 1 capsule twice a day from Day 0 to Week 24

DRUG

Daclatasvir

Daclatasvir 60 mg, 1 tablet once a day from Day 0 to Week 24

DRUG

Ribavirin

Ribavirin tablets or capsules 200 mg, weight-based daily dose ( \<75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), from Day 0 to Week 24

DRUG

Pegylated Interferon alpha-2a

Pegylated Interferon alpha-2a, by subcutaneous injection 180µg / week, from Day 0 to Week 24

Trial Locations (25)

13285

Fondation Hôpital Saint Joseph, Marseille

31059

Hôpital Purpan, Toulouse

33601

Hôpital de Haut Lévêque, Bordeaux Pessac

34295

Hôpital Saint Eloi, Montpellier

35000

Hôpital Pontchaillou, Rennes

38043

Hôpital Albert Michallon, Grenoble

44093

Hôpital de l'Hôtel Dieu, Nantes

54511

Hôpital de Brabois, Nancy

59037

Hôpital Claude Huriez, Lille

69317

Hôpital de la Croix Rousse, Lyon

75571

Hôpital Saint Antoine, Paris

75651

Hôpital Pitié Salpêtrière, Paris

75679

Hôpital Cochin, Paris

75970

Hôpital Tenon, Paris

76031

Hôpital Charles Nicolle, Rouen

87042

Hôpital Dupuytren, Limoges

92110

Hôpital Beaujon, Clichy

93009

Hôpital AVICENNE, Bobigny

93140

Hôpital Jean Verdier, Bondy

94010

Centre Hospitalier Intercommunal, Créteil

Hôpital Henri Mondor, Créteil

94804

Hôpital Paul Brousse, Villejuif

06202

Hôpital de l'Archet, Nice

Unknown

Hôpital de La Source, Orléans

06721

Institut Arnault Tzank, Saint-Laurent-du-Var